Thailand Medical Device Registration: How Should Multiple Models Be Grouped for Submission?

Answer: For medical device registration in Thailand, multiple models are generally grouped for submission after the product classification and applicable regulatory pathway are confirmed. The dossier should then be prepared with a model and specification matrix, technical file, labels and instructions for use, quality management system evidence, authorization documents, and local representative information. Existing NMPA documents may serve as a basis, but they usually need to be adapted to Thailand TFDA requirements for language, format, labeling, and evidence chain. A reliable approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Final grouping should be confirmed against current TFDA requirements and the product evidence base.

Published: 2026-07-10 13:08 | Updated: 2026-07-10 13:08

This FAQ addresses priorities that companies should assess in actual international medical device registration projects, including dossier preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Assessment Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Further Reading
• Applicability Boundaries

Key Summary

Thailand medical device registration usually requires first confirming the product classification and applicable pathway, then preparing the technical file, labels and instructions for use, quality management system evidence, authorization documents, and local representative information. Existing NMPA documents can be used as a basis, but they usually need language, format, labeling, and evidence-chain adaptation according to Thailand TFDA requirements.

For Chinese medical device companies, a more reliable approach is to first perform product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused.

Thailand registration often affects the technical file, authorized representative, importer cooperation, label language, quality management system evidence, and subsequent change maintenance at the same time. If the project is advanced only by asking which documents to submit, corrections or rework can easily occur in model coverage, evidence-chain consistency, label claims, and certificate control. AIMEILI recommends putting this question into a unified plan for GHWP member states and multi-country market access, using one reusable core technical file to support localization in different markets rather than recreating documents temporarily for each country.

Companies should also make project-based judgments based on the latest requirements of the target country regulator, the existing technical file basis, product risk level, and launch plan, avoiding mechanical preparation based only on a document checklist.

Compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for how to group multiple models for medical device registration in Thailand generally want to solve practical questions rather than obtain a conceptual explanation: whether existing documents can support a Thailand submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first make the core technical file, quality management system evidence, performance verification, clinical evidence, and labels and instructions for use into reusable versions, and then localize them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body-contact method, duration of use, sterility, whether it is powered, and whether it includes software or IVD attributes, then determine the risk class and submission pathway. Once the pathway assessment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate from the correct direction.

For a Thailand project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely only in a commercial contract, they can easily affect market control later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality management system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. Instructions-for-use claims, models covered by test reports, applicable scope of clinical evidence, risk management conclusions, label warnings, and information in the registration application form must support each other. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

The most common problem is treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without reorganizing the evidence according to the Thailand pathway.
• Having too many model specifications while test reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent only on the basis of sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistency among labels, instructions for use, promotional materials, and registration claims, leading to corrections or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, causing repeated preparation for each country and amplifying cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation basis and avoid discovering critical evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the local agent's or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not understand Thailand registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix and then converting it according to country requirements is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway assessment; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documents appear extensive, the project may still encounter repeated issues during corrections, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be used directly for Thailand registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustment, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market incident handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, quality management system documents are not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the products being submitted, or if the manufacturing address, model specifications, instructions-for-use version, and test reports are inconsistent, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions-for-use version, and quality management system certificate item by item. This action appears basic, but it can significantly reduce the probability of corrections, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Thailand registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transportation conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model expansion, instructions-for-use update, or agent replacement later occurs, the certificate can easily become disconnected from market sales.

AIMEILI recommends that companies incorporate this question into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, corrections, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but more importantly enabling companies to form a replicable compliance capability for going global and reducing the cost of organizing documents from scratch each time they enter a new market.

Further Reading

Previous: What should be prepared before renewing medical device registration in Thailand?

Next: What are the requirements for risk management documents for medical device registration in Thailand?

Recommended Reading

• How should registration documents be prepared for medical device registration in Malaysia?
• How should product classification be determined for medical device registration in Malaysia?
• How should the technical file be organized for medical device registration in Malaysia?
• How should labels and instructions for use be localized for medical device registration in Malaysia?
• How should clinical evaluation documents be prepared for medical device registration in Malaysia?
• Can test reports be reused for medical device registration in Malaysia?

Return to FAQ Center

News and Information

Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicability boundary: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country regulator, testing conclusions, or legal advice.